Source Report

Total Addressable Market for Pharma RWD Licensing

Tempus leverages its multimodal oncology dataset—combining de-identified clinical notes, genomic sequencing from 300,000+ patients, and imaging—to enable pharma partners to train foundation models that identify novel drug targets 3-5x faster than traditional methods, as seen in its $200 million AstraZeneca/Pathos deal where real-time sales-linked repayment reduces lender risk compared to banks' collateral-heavy loans.[1][2]
- Global RWD market valued at $2.34 billion in 2026, projected to reach $4.21 billion by 2030 (15.8% CAGR), driven by AI analytics and regulatory acceptance of RWE for approvals[3]
- Pharma end-users dominate (~60% share), using RWD for trial design, patient matching, and post-market surveillance; oncology RWD subsets growing fastest at 16-18% CAGR[4]
- Related RWE solutions market at $5.42 billion in 2025, expanding to $10.8 billion by 2030 (14.8% CAGR), with AI-powered subsets (e.g., Tempus-style models) accelerating due to FDA/EMA guidelines[5]

Implications for competitors: New entrants must build proprietary multimodal datasets (clinical + genomic + imaging) exceeding 1 million records for defensible moats, as commoditized claims/EHR data alone yields inferior AI models; partner with sequencers like Illumina early to capture longitudinal outcomes.

Tempus's Pharma Partnerships and Strategic Edge

Tempus's platform aggregates real-time multimodal data (8 million+ de-identified records delivered to pharma) via 700+ integrations across 5,000+ sites, enabling "just-in-time" trial matching where AI stratifies patients by molecular/clinical profiles in hours vs. months, powering 19/20 top pharmas and yielding >$1.1 billion TCV (up from $940 million in 2024).[6][7]
- Key deals: $200 million (2025) data licensing/modeling with AstraZeneca/Pathos for world's largest oncology foundation model; expansions with GSK ($70 million upfront for 3 years), Pfizer, BMS[1][8]
- 70+ new 2025 agreements (AstraZeneca, GSK, Pfizer, Novartis, Merck, Lilly); 126% net revenue retention reflects expansions (e.g., Insights licensing up 69%)[7]
- TCV breakdown: ~$350 million for 2026 visibility; includes $300 million opt-ins; Data/Apps revenue hit $316 million in 2025 (31% YoY)[9]

Implications for competitors: Oncology specialists like Tempus hold data moats from sequencing flywheels (31,000+ annual samples), forcing generalists to acquire (e.g., Roche's $1.9 billion Flatiron buy) or partner; mid-sized pharmas entering via Tempus-like platforms gain 2-3x faster target ID but risk vendor lock-in without multi-sourcing.

Contract Structures: Subscriptions vs. Milestones

Tempus structures deals as multi-year data licensing with upfront fees + usage-based milestones tied to model milestones (e.g., $200 million AstraZeneca/Pathos: licensing + development fees), blending subscription-like access to longitudinal datasets with performance triggers that align incentives and auto-renew via opt-ins, yielding 126% retention vs. pure milestone risks.[1]
- Tempus/GSK: $70 million upfront for 3-year access + task orders for screening/services[8]
- IQVIA: "Data as a Service" subscriptions for harmonized RWD (EHR/claims), milestone-heavy for custom RWE studies; no specific sizes disclosed but powers 90% global pharma tracking[10]
- Flatiron (Roche-owned): Licensing to pharmas pre-acquisition; now internal + partnerships (e.g., Sanofi trials); structures undisclosed but EHR-derived RWD favors subscriptions[11]

Implications for competitors: Hybrid models (upfront 30-50% + milestones/opt-ins) de-risk for cash-strapped biotechs while ensuring vendor revenue durability; pure subscriptions commoditize data, eroding pricing power amid AI commoditization.

Competitive Dynamics Among Key Players

IQVIA dominates with 25%+ U.S. RWE share via 1.2 billion patient records (claims/EHR), powering analytics platforms where AI harmonizes multi-source data for 90% global pharma sales tracking, outpacing oncology-focused rivals through scale but lagging Tempus/Flatiron in multimodal depth.[12]
- IQVIA/Flatiron/Tempus top-5 (85% U.S. RWE share combined); Tempus leads oncology AI (>$1.1B TCV, 70+ deals); Flatiron (Roche) excels EHR curation (5M+ records)[13]
- Veeva/Medidata: Platform plays (Vault CTMS/Rave EDC); Acorn AI for commercial insights, not pure RWD licensing; compete via integrations (e.g., Medidata's 36,000 trials)[14]
- Tempus differentiation: Genomic flywheel (80,000+ Algos ordered) enables superior oncology models vs. IQVIA's claims-heavy data[15]

Implications for competitors: Scale players (IQVIA) win breadth; specialists (Tempus oncology) capture premiums via vertical moats; platforms (Veeva/Medidata) bundle RWD into SaaS, pressuring pure licensors to API-integrate or face disintermediation.

Revenue Durability Amid Budget Cycles and AI In-Housing

Pharma R&D budgets rose 8-10% in 2025 ($200B+ global), sustaining RWD demand despite cycles, as AI shifts from experimentation (17% measurable R&D ROI) to core (50% expect 2026 value), favoring durable licensing over one-offs; in-housing limited by data moats (e.g., Tempus's 126% retention proves stickiness).[16]
- 77% pharma uses RWD; 54% AI-integrated; value-based care mandates ongoing RWE for pricing/reimbursement[17]
- Trends: Quality > quantity RWD; AI precision (e.g., Tempus models) locks in multi-year deals; regulatory scrutiny favors verified providers[18]
- Durability: TCV models (Tempus $1.1B) buffer cycles; 99% plan trial inclusivity via RWD/AI[19]

Implications for competitors: Revenue stable via subscriptions/opt-ins (40%+ growth projected); counter in-housing by federated learning APIs allowing pharma AI on vendor data without transfer, preserving moats while enabling "AI factories."[20]

---

Recent Findings Supplement (March 2026)

Tempus's Surging Data Licensing Momentum

Tempus AI solidified its position as the leading AI-enabled RWD provider to pharma by announcing a record Total Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025—up from $940 million at end-2024—fueled by 70+ new data agreements with majors like AstraZeneca, GSK, BMS, Pfizer, Novartis, Merck, AbbVie, Daiichi Sankyo, Eli Lilly, and Boehringer Ingelheim; this reflects pharma's shift to Tempus's multimodal (genomic + clinical) dataset for biomarker discovery, where real-time longitudinal linkages enable causal AI models that predict resistance mechanisms banks of traditional data can't match, turning raw RWD into proprietary drug hypotheses.[1][2]
- Data & apps revenue hit ~$316 million in 2025 (31% YoY growth), with Insights (licensing) up 38%; net revenue retention at 126% shows expansions outpacing churn.[3]
- March 3, 2026: Expanded multi-year Merck deal grants access to Lens platform + GPU-powered Workspaces for oncology biomarker ID and combo testing, initially oncology but expandable—positioning Tempus as Merck's core AI data partner post-Keytruda.[4]
Implication for competitors: Tempus's scale (200+ biopharma clients) creates a flywheel where more data refines AI, locking in renewals; Flatiron/IQVIA must accelerate multimodal oncology linkages or risk commoditization.

Medidata's AI Study Build Expansion in Oncology Trials

Medidata (Dassault Systèmes) expanded its 14-year partnership with Menarini Group/Stemline Therapeutics on March 9, 2026, deploying AI Study Build to auto-generate protocols from vast historical clinical datasets, slashing trial startup from months to days by matching patient cohorts to protocols via NLP on EDC/eCOA data—enabling Stemline's first fully in-house oncology study while retaining Medidata's platform lock-in.[5]
- Builds on Medidata Rave EDC + eCOA; AI leverages "vast clinical data set" for independence in global oncology pipeline acceleration.[6]
- Recent CRIO integration eliminates double-entry across 2,500 sites, feeding cleaner RWD into AI workflows.[7]
Implication for competitors: Veeva/Medidata's AI-native trial design moats trial ops; IQVIA must integrate its RWD faster into similar tools, or lose to platforms owning the data-to-protocol pipe.

Flatiron's AI-Extracted RWD Datasets Go Global

Flatiron (Roche) launched AI-powered Panoramic prostate cancer datasets in UK/Germany (Feb 2026), using VALID Framework (F1 scores matching human abstractors across 14 cancers) to extract progression/biomarker data from EHRs at scale—expanding its 5M+ patient repository (1.5B data points) beyond US, enabling cross-border RWE for post-market Phase IV trials.[8]
- Paradigm acquired Flatiron's clinical research arm (Dec 2025) for embedded Phase IV in routine care, generating RWD for 23 NCI sites.[9]
- Hematology datasets grew 6x to 505K patients (Oct 2025), with "digital twin" OS prediction via LLM-extracted variables.[10]
Implication for competitors: Flatiron's oncology RWD depth forces Tempus/IQVIA to match AI validation rigor; new entrants need EHR partnerships to compete in global expansion.

IQVIA-Veeva Tie-Ups Bolster RWD Interoperability

IQVIA renewed RWD pact with Institut Curie (Nov 2025, 3 years) for cancer insights, while Oct 2025 Veeva partnership enables IQVIA OneKey data flow into Vault/CRM via TPAs (issued in 10 days)—unlocking master data management for HCP linking without rebuilds, as pharma shifts to hybrid data ecosystems.[11][12]
- Sep 2025: IQVIA-Veeva decentralize trials via CRO + Vault tech integration.[13]
Implication for competitors: Interop wins (e.g., IQVIA's 1.2B records) favor incumbents; Tempus must API its Lens platform broadly or cede to ecosystem plays.

RWD/RWE TAM Estimates Converge on $3-6B in 2025, Explosive Growth Ahead

Analyst consensus pegs global RWE solutions TAM at $3.0-3.3B in 2025 (pharma ~45% share), growing to $6-11B by 2034-35 at 8-16% CAGR—driven by AI curation of EHR/claims for regulatory/payer use, with pharma prioritizing oncology/cardio; no pharma-specific licensing TAM disclosed, but Tempus's $1.1B TCV implies 20-30% capture in data subset.[14][15][16]
- RWD market: $1.9-3.3B (2025) to $6-7B (2034), AI-powered at 14.8% CAGR.[17]
- US RWE: $1.1B (2025) to $4.1B (2034), IQVIA/Flatiron ~85% share.[18]
Implication for competitors: Fragmented $3B+ TAM rewards AI scale; in-housing trends (pharma building AI on licensed data) sustain licensing if providers like Tempus offer GPU compute moats.

Revenue Durability Amid AI In-Housing and Budget Pressures

Pharma AI budgets split: quick wins (data ops/commercial, 47-49% proving value) vs. long-cycle R&D (17-30% now, 42-45% in 2026), with RWD fueling clinical planning/recruitment; in-housing rises (e.g., AstraZeneca's Modella AI), but hybrid prevails—licensing RWD as "fuel" persists as pharmas lack multimodal depth/Tempus-scale linkages, buffering budget cycles via NRR like Tempus's 126%.[19]
- No direct in-housing threats to licensing; pharma invests $6-9B in RWD (2024 est.), with 45-60% programs yielding value (15-35% enrollment cuts).[20]
Implication for competitors: Durable if AI+RWD combos (e.g., Tempus Lens) exceed in-house baselines; monitor pharma M&A (licensing $232B in 2025) for data asset grabs.[21]